ARDS - Aridis Pharma up 7% on potential inhaled therapy for COVID-19

Ultra-thinly traded nano cap Aridis Pharmaceuticals (ARDS) perks up 7% premarket on light volume in reaction to its announcement of preclinical data supporting the potential efficacy of an inhalable formulation of AR-711, a neutralizing monoclonal antibody, for treating COVID-19.In a Syrian hamster study, the delivery of AR-711 directly to the lungs eliminated all detectable SARS-CoV-2 virus at substantially lower doses compared to parenteral administration.A clinical trial assessing AR-711, discovered from COVID-19 patients who had recovered from the infection, in non-hospitalized COVID-19 patients with mild-to-moderate symptoms should launch in H1 2021.

For further details see:

Aridis Pharma up 7% on potential inhaled therapy for COVID-19